Monocyte products probably play a role in the initiation of smooth muscle cell proliferation in the arterial wall early in atherogenesis. Several groups have described mitogenic activity for arterial smooth muscle cells that is elaborated by mononuclear phagocytes (macrophage-derived growth factor). However, the biochemical nature of this mitogenic activity is unknown, lnterleukin-1 (IL-1) is a well-characterized monocyte product that activates the growth of mitogen-stimulated lymphocytes and promotes the growth of fibroblasts. We tested whether IL-1 also affects the growth of arterial smooth muscle cells and might account for some of the mitogenic activity produced by activated monocytes. Highly purified human IL-1 did stimulate the growth of human fibroblasts of either adult or fetal origin. However, under identical conditions, IL-1 lacked significant mitogenic effects on human, bovine, rabbit, or canine arterial smooth muscle cells. This mediator also failed to stimulate the growth of cultured human or bovine vascular endothelial cells, another cell type that may respond to macrophage-derived growth factor, lnterleukin-1 did not render smooth muscle cells competent to divide in the presence of plasma factors such as insulin (1(H M), or when growth of muscle cells was limited by incubation in a low (2%) concentration of serum. This monokine also failed to increase the mitogenic effect of purified platelet-derived growth factor on arterial smooth muscle cells incubated in serum-free medium. Thus, cultured human arterial smooth muscle cells differ from fibroblasts and lymphocytes in their response to human IL-1. Furthermore, since IL-1 lacks direct mitogenic effects on vascular smooth muscle cells, it does not account for the growth-promoting activity for smooth muscle cells that is elaborated by activated macrophages (macrophage-derived growth factor).
sis, leukocyte infiltration of the vascular wall can precede the hyperplasia of smooth muscle cells. 2 " 7 Early after institution of a high cholesterol diet in swine or monkeys, monocytes adhere to the arterial intima, penetrate into the subendothelial area, and form foam cells. 5 -7 In cholesterol-fed monkeys, such foam-cell lesions can evolve into fibrous plaques. 8 Monocytic infiltration of the intima is also prominent in young rabbits with spontaneous hypercholesterolemia, due to a defect in their receptors for low density lipoprotein (WHHL mutation). 9 These mutant rabbits may eventually develop lesions that resemble complicated human atherosclerotic plaques. 10 In humans, systematic observations on early atheromata are unavailable, although advanced human lesions do contain cells of probable monocyte origin. 1112 Although monocytes are situated at an appropriate location at the right time to play an important role in the initiation of atherosclerosis, little is known of the possible mechanisms of mononuclear cell interaction with vascular wall cells. An attractive possibility is suggested by recent observations that macrophages and human peripheral blood monocytes can produce material that stimulates the proliferation of vascular smooth muscle cells and fibroblasts. 113 - 14 Such a mediator could link early inflammation to initiation of an intimal proliferative lesion in arteries. However, this growth-promoting activity, termed "macrophage-derived growth factor (MDGF)," has not yet been fully characterized biochemically.
lnterleukin-1 (IL-1) is a well-defined monocyte product that is known to be mitogenic for dermal and synovial fibroblasts, and to augment lymphocyte proliferation in response to a variety of mitogens. 15 lnterleukin-1 is also chemotactic for neutrophils and lymphocytes and mediates several components of the acute-phase, protein synthesis by liver and proteolysis in skeletal muscle. 15 Because of the possible importance of monocyte-smooth muscle cells interaction in early atherogenesis, we investigated the effects of this important mediator on vascular smooth muscle cells.
Methods

Cell Preparations
Human arterial smooth muscle cells were prepared by explant outgrowth techniques from punch specimens of clinically undiseased portions of the aorta obtained from patients undergoing coronary artery bypass grafting or from grossly normal aortas obtained at autopsy. 16 The use of normally discarded tissues obtained at surgery was approved by the Human Investigation Review Board of New England Medical Center. Explants were incubated in Dulbecco's modified Eagle's medium that contained 10% fetal calf serum. After 10 to 20 days, outgrowth of smooth muscle cells from these explants was sufficient to permit harvesting with a solution of trypsin (1.0 mg/ml) and ethylenediamine tetraacetic acid (2 mm) in Earles' balanced salt solution buffered with hydroxyethylpiperazine sulfonic acid (20 mM). The cells were then frozen by using dimethylsulfoxide (5%) as a cryopreservative, or were subcultured directly into 24-well plates (surface area 2 cm 2 per well). Only first through third subcultures of these human arterial smooth muscle cells were used in these experiments. Bovine and rabbit aortic smooth muscle cell cultures were obtained by similar procedures, and were used in their first subculture.
Adult human saphenous vein endothelial cells were prepared from excess portions of human saphenous veins obtained at cardiac surgery. 17 The vessel segment was rinsed with tissue-culture medium to remove blood and was filled with a solution of bacterial collagenase (Worthington type II, 0.1%) and bovine serum albumin (0.5%) in Dulbecco's phosphate-buffered saline (PBS). After 30 minutes of incubation at 37° C, the digest was collected, and the vessel was rinsed with Medium 199 (M-199). This cycle was repeated twice. The cells were sedimented at 100 g and resuspended in M-199 supplemented with fetal calf serum (FCS, 5%), endothelial cell growth factor (50 fj.g/m\), and porcine heparin (100 ^g/ml). The resuspended cells were plated on plastic coated with human fibronectin (1.5 /xg/cm 2 ). These cells were stained in a punctate or rod-like pattern for factor Vlll-related antigen as determined by indirect immunofluorescence utilizing rabbit antihuman factor VIM as the primary antibody and fluorescine isothiocyanate (FITC)-conjugated goat antirabbit antiserum as the secondary antibody.
Human fibroblasts were prepared from foreskins of neonates by dissociation in Hanks' balanced salt solution lacking divalent cations and containing collagenase (2 mg/ml). These cells were used from Passages 3 to 16. Adult human dermal fibroblasts were kindly provided by Dr. Barbara Gilchrest (Tufts University).
Growth Assays
Increases in cell numbers can be unreliable indices of smooth muscle cell growth because of the artifacts associated with producing single cell suspensions from cultures incubated under different conditions. Growing smooth muscle cells produce an elaborate extracellular matrix that can hinder enzymatic dispersion of the cells without producing cell lysis. Likewise, uptake of tritiated thymidine is not always a reliable index of cell growth. Therefore, we measured the accumulation of DNA and protein by the cell cultures in addition to the thymidine incorporation. These independent indices of cell growth do not depend on assumptions about the specific radioactivity of precursor pools and are independent of problems with obtaining single cell suspensions. 18 DNA was measured fluorimetrically with the intercalating agent, bisbenzamid. 19 The cultures were treated with perchloric acid (0.2 M) to precipitate macromolecules and were washed with Hank's balanced salt solution. The fixed-cell layer was dissolved in a solution of sodium dodecylsulfate (SDS, 0.1%) in sodium hydroxide (0.01 M). The well was then rinsed with an equal volume of SDS (0.1%). These solutions were combined and the DNA was determined using calf thymus DNA as a standard. Protein was determined on these digests by the fluorescamine method using bovine serum albumin (fraction V) as a standard. 20 Tritiated thymidine incorporation was measured by adding the isotopically labeled precursor (Schwartz-Mann, 6 mCi/mm, 1.0 /xCi/ml final concentration) to the individual wells 24 hours after exposure to the test substance. After 48 hours of contact with the test substance, the experiment was stopped by acid precipitation, as described above. Samples of the cell extract were prepared for liquid scintillation spectroscopy. The efficiency of counting was determined using a calibrated external standard.
Preparation and Assay of lnterleukln-1 and Monocyte Supernatants
Human monocyte supernatants were prepared from platelet-pheresis byproducts. These leukocyte concentrates were separated by Ficoll-Hypaque density gradient centrifugation. The population of adherent cells obtained in this manner were stimulated by heat-killed Staphylococcus albus, as described previously. 21 The medium that was elaborated for the first 24 hours after stimulation in vitro was collected, centrifuged at 25,000 g, concentrated in Spectropore 3 dialysis tubing with the use of polyethylene glycol 6000, and dialyzed against PBS. This concentrate was applied to a column (5 x 170 cm) of Sephadex G-50 (fine) and eluted with saline (NaCI 0.15 M, pH 5.6-5.9,4° C). Fractions that eluted in the estimated molecular weight range of 15,000 to 20,000 were assayed for IL-1 activity by measuring the incorporation of tritiated thymidine into mouse thymocytes stimulated with suboptimal concentrations of phytohemagglutinin (1 /u,g/ml), as described previously. 22 The active fractions were pooled and concentrated as described above, and on the day of study were dialyzed against culture medium in the presence of human serum albumin (0.1%). For many experiments, IL-1 was first purified from the monocyte supernatants on an anti-IL-1 antibody-Sepharose 4B column, and then chromatographed by gel filtration as above. 23 In addition to characterization by the lymphocyte activation assay described above, each preparation of IL-1 was tested for pyrogenicity in rabbits. One pyrogen unit of IL-1 is the dose required to raise the rectal temperature of rabbits 0.6°-0.9° C within 60 minutes following intravenous injection. One pyrogen unit corresponds to 1000 to 10,000 units of IL-1 as estimated by the lymphocyte activation assay. The units reported in this paper are those determined by the lymphocyte activation assay.
Results
Monocyte supernatants promoted the growth of arterial smooth muscle cells and human fibroblasts under the conditions of our experiments (Figure 1 ) and as shown previously by others. 13 ' 14 Growth-pro- moting effects were documented by increased incorporation of tritiated thymidine (Figure 1 ). In other experiments not shown, monocyte-conditioned medium also increased DNA and total protein contents and stimulated protein synthesis by cultures of human smooth muscle cells and fibroblasts.
Highly purified human IL-1 also stimulated proliferation of human fibroblasts both from neonates and an adult ( Figure 1 , Table 1 , and data not shown), in accord with previous observations. 24 This monokine increased the tritiated thymidine uptake into macromolecules of human fibroblasts in a concentrationdependent manner (Figure 1 ). Changes in this index of DNA synthesis corresponded to the actual net increases in DNA content (Table 1 ) and protein content (data not shown) of fibroblast cultures exposed to IL-1.
In contrast, IL-1 did not stimulate the growth of arterial smooth muscle cells of human, bovine, canine, or rabbit origin by any of the criteria studied ( Table 1, Figures 1 and 2 , and data not shown). These various smooth muscle cell isolates were all These three experiments were performed in parallel with the same preparation of IL-1 that was purified by both gel filtration and antibody affinity chromatography. Human fibroblasts were obtained from neonates. TDR = tritiated thymidine. FCS = fetal calf serum. capable of a mitogenic response under the conditions of these experiments, as shown by the stimulation produced by bovine sera (Figures 1 and 2 , Table 1 ).
Cells exposed to certain mitogens (termed "competence factors") require the presence of complementary factors in the medium ("progression factors") in order to complete the cell cycle. 25 Thus, it was possible that the lack of mitogenic response of smooth muscle cells to purified IL-1 in serum-free The DNA content at the beginning of the 48-hour incubation was 5.0 ± 0.3 ^g/well. In no case did the addition of IL-I cause a statistically significant increase in DNA content.
In other experiments, we found that the addition of a human serum fraction enriched in somatomedins and dexamethasone (10~9 M) did not lead to mitogenic responses of these cells. tissue culture medium might be due to a lack of such complementary factors in vivo. Accordingly, we assayed IL-1 for growth-promoting effects on bovine smooth muscle cells in medium supplemented with insulin (10-6 M), with or without transferrin and arachidonic acid bound to bovine serum albumin, or calf serum at growth-limiting concentrations (2%). Arachidonic acid was added because its metabolites may mediate some of the effects of IL-1, 15 Even under these various conditions, we were unable to elicit a mitogenic effect with the purified IL-1 ( Table 2) .
Further experiments tested whether purified IL-1, although lacking competence factor activity for smooth muscle cells, could serve as a progression factor for platelet-derived growth factor, a well-characterized "competence" factor for human and bovine aortic smooth muscle cells. This possibility would be compatible with the observation that IL-1 is not itself a mitogen for thymocytes, but potentiates the effect of suboptimal concentrations of bona fide lymphocyte mitogens such as the lectin phytohemagglutinin. 15 These experiments were performed in serum-free medium containing human serum albumin (0.1%). A submaximal concentration of highly purified platelet-derived growth factor (2 ng/ml 26 ) stimulated both uptake of tritiated thymidine and increase in DNA content in these cells (Figure 3 ). Addition of IL-1 (200 U/ml) did not further stimulate growth of these cells. A parallel experiment using bovine aortic smooth muscle cells also showed no potentiation of platelet-derived growth factor (PDGF) by IL-1 (data not shown).
To test whether a longer exposure to IL-1 might stimulate smooth muscle proliferation, we added IL-1 to serum-free medium, or to medium containing limiting concentrations of fetal calf serum (2%), over a 10-day period. Incubation with fetal calf serum (10%) markedly increased both DNA and protein content of the cultures after 10 days ( Figure 2 ). In contrast, IL-1, either in the presence or absence of fetal calf serum (2%), had no effect on the growth rate of the human smooth muscle cells. This experiment supports our other evidence that IL-1 is not a competence factor for smooth muscle cells.
Supernatants of activated monocytes stimulate the division of bovine aortic endothelial cells as well as smooth muscle cells and fibroblasts. 14 We therefore tested the effect of purified IL-1 on the growth of both adult human and bovine endothelial cells. Interleukin-1 did not stimulate growth of either human or bovine endothelial cells determined by accumulation of DNA and protein ( Table 3 ). Addition of serum to these cells did stimulate growth, as determined by these criteria. Even during coincubation with limiting concentrations of calf serum (2%), highly purified human IL-1 failed to influence the growth of human endothelial cells.
Discussion
These results clarify the responses of mesenchymal cells to the monocyte-derived protein IL-1 in several ways. First of all, we showed that of the many substances released by stimulated human monocytes, IL-1 was not responsible for signaling the growth of smooth muscle cells. Thus, human monocytes must produce at least two distinct mitogenic activities for mesenchymal cells: 1) lnterleukin-1, which directly stimulates fibroblast growth but does not stimulate endothelial or smooth muscle cells, and 2) MDGF, which does promote growth of these vascular cells.
This evidence for the lack of identity of the MDGF and IL-1 is consistent with the findings that mouse mononuclear phagocytes stimulated in vitro, and a mouse macrophage-like tumor cell line (P388D) secrete a factor that stimulates proliferation of fibroblasts but that appears to have physiochemical characteristics distinct from those of IL-1. 1427 These various in vitro findings also correlate well with recent evidence that macrophages activated in vivo elaborate substances that promote fibroblast growth but that lack IL-1 (thymocyte activating) activity. 2829 A second interesting aspect of these results is the clear-cut difference in the response of fibroblasts and smooth muscle cells to IL-1 in homologous human preparations ( Table 1 ). The ability of IL-1 to stimulate proliferation of human fibroblasts is consistent with the data of Schmidt et al. 24 While even very highly purified IL-1 is mitogenic for human fibroblasts from several sources, we were unable to demonstrate such an effect on arterial smooth muscle cells under a wide variety of conditions, lnterleukin-1 was unable to stimulate growth of smooth muscle cells even in the presence of limiting concentrations of serum, or growth-related serum constituents, including supraphysiologic concentrations of insulin (Table 2, Figure 2 ). At such levels, insulin can cross-react with the receptor for somatomedin-C 30 and may act as a "progression factor" that permits mitogen-stimulated cells to complete the cell cycle. Thus, IL-1 does not appear to have "competence factor" activity. In addition, IL-1 did not potentiate the effect of purified PDGF (a "competence" factor) on the growth of smooth muscle cells in plasma-free medium, indicating that it cannot serve as a "progression" factor ( Figure 3) .
A third important conclusion is the finding that IL-1 is not a nonspecific mitogen that causes growth of all cell types indiscriminately. Rather, this monokine appears to have a restricted range of targets since it does not stimulate division of vascular smooth muscle or endothelial cells. The inability of IL-1 to stimulate growth of these vascular wall cells was not due to a difference in species from which the cells were derived. We evaluated the effects of IL-1 on arterial smooth muscle cells from four species including well-characterized bovine cells, canine coronary artery cells prepared by enzymatic dissociation, human cells from a variety of donors, and cells from the rabbit, the species used for the pyrogen assay for human IL-1. This differential growth response of fibroblasts and smooth muscle cells is unusual, and may prove useful in understanding differences between these two mesenchymal cell types that closely resemble one another, particularly in vitro. 
